Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial

and objectives The Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 study demonstrated a significant beneficial effect of the vasopressin V2 receptor antagonist tolvaptan on rates of kidney growth and eGFR decline in autosomal dominant...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical journal of the American Society of Nephrology 2016-05, Vol.11 (5), p.803-811
Hauptverfasser:	Torres, Vicente E, Higashihara, Eiji, Devuyst, Olivier, Chapman, Arlene B, Gansevoort, Ronald T, Grantham, Jared J, Perrone, Ronald D, Ouyang, John, Blais, Jaime D, Czerwiec, Frank S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Albuminuria - etiology Antidiuretic Hormone Receptor Antagonists - adverse effects Antidiuretic Hormone Receptor Antagonists - therapeutic use Benzazepines - adverse effects Benzazepines - therapeutic use Disease Progression Double-Blind Method Female Glomerular Filtration Rate - drug effects Humans Hypernatremia - chemically induced Hypertension - etiology Kidney - diagnostic imaging Kidney - pathology Magnetic Resonance Imaging Male Middle Aged Organ Size - drug effects Original Pain - etiology Polycystic Kidney, Autosomal Dominant - complications Polycystic Kidney, Autosomal Dominant - drug therapy Polycystic Kidney, Autosomal Dominant - physiopathology Severity of Illness Index Tolvaptan
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!